iRhythm Holdings, Inc. Common Stock
IRTCiRhythm Technologies, Inc. is a healthcare company specializing in the development and commercialization of wearable biosensing devices and cloud-based data analysis tools for cardiac monitoring. Its flagship product, the Zio service, provides ambulatory ECG monitoring to detect arrhythmias, enabling improved diagnosis and management of cardiovascular conditions. Founded in 2006 and headquartered in San Francisco, iRhythm aims to enhance patient care through innovative digital health solutions.
Company News
iRhythm Holdings disclosed a cybersecurity incident involving unauthorized access to sensitive data on third-party-hosted business applications. A threat actor claimed possession of proprietary company data and patient health information, demanding payment to prevent public disclosure. The company confirmed data exfiltration but stated core opera...
iRhythm Technologies reported strong preliminary Q4 2025 results with full-year revenue exceeding guidance and 2026 guidance of $870-880M (17-18% YoY growth). However, the stock fell ~20% due to the delay of Zio MCT launch to 2027 and 2026 guidance missing Street expectations. William Blair analyst Brandon Vazquez believes the selloff is overblow...
NEXGEL reported stable Q3 2025 revenue of $2.9 million, improved gross profit margins, and narrowed adjusted EBITDA losses. The company signed new partnerships, launched product lines, and received non-dilutive financing from Stada, positioning for potential growth in Q4.
The global cardiac monitoring devices market is projected to grow from USD 21 billion in 2024 to USD 32 billion by 2032, driven by rising cardiovascular disease prevalence, technological advancements in remote monitoring, and increasing health awareness.
A clinical trial showed home-based long-term continuous ECG monitoring using Zio device increased atrial fibrillation detection and reduced time to diagnosis in patients aged 65+ with moderate to high stroke risk.
